SEARCH

SEARCH BY CITATION

References

  • 1
    Antihypertensive Therapy and Lipid Lowering Heart Attack Trial (ALLHAT) Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2000;283:19671975.
  • 2
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393404.
  • 3
    Ames RP. The influence of non β-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension? Am Heart J. 1987;114:9981006.
  • 4
    Zussman RM. Alternatives to traditional antihypertensive therapy [editorial]. Hypertens. 1986;8:837842.
  • 5
    Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J. 1989;117:911949.
  • 6
    Hebert P, Moser M, Mayer J, et al. Recent evidence of drug therapy on mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578581.
  • 7
    McInnes GT, Yeo WW, Ramsey LE, et al. Cardiotoxicity and diuretics: much speculation, little substance. J Hypertens. 1992;10:317335.
  • 8
    Moser M. Suppositions and speculations—their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118:13621369.
  • 9
    Freis ED. Critique of the clinical importance of diuretic induced hypokalemia and elevated cholesterol levels. Arch Intern Med. 1989;149:26492658.
  • 10
    Moser M. Current hypertension management: separating fact from fiction. Cleve Clinic J Med. 1993;60:2737.
  • 11
    Thompson WG. An assault on old friends: thiazide diuretics under siege. Am J Med Sci. 1990;300:152158.
  • 12
    Papademetriou V, Fletcher R, Khatri IM, et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med. 1988;148:12721276.
  • 13
    Holland OB, Nixon JV, Kuhnert I. Diuretic-induced ventricular ectopic activity. Am J Med. 1981;770:762768.
  • 14
    Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med. 1984;80(4A):2832.
  • 15
    Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in the hypertension treatment trials. J Am Coll Cardiol. 1996;27:12141218.
  • 16
    The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:17951801.
  • 17
    The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1993;153:154183.
  • 18
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:24132446.
  • 19
    Moser M, Blaufox MD, Freis E, et al. Who really determines your patients' prescriptions? JAMA. 1991;265:498500.
  • 20
    Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;179:18131816.
  • 21
    SHEP Cooperative Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 22
    Moser M. Diuretics should continue to be recommended as initial therapy in the treatment of hypertension. In: PuschettJB, GreenbergA, eds. Diuretics IV: Chemistry, Pharmacology and Clinical Applications. New York , NY : Exerpta Medica; 1993:465477.
  • 23
    Neaton JD, Grimm RH, Prineas RJ, et al. for the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension study: final results. JAMA. 1993;270: 713724.
  • 24
    Moser M, Setaro J. Antihypertensive drug therapy and regression of left ventricular hypertrophy: review with a focus on diuretics. Eur Heart J. 1991;12:10341039.
  • 25
    Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care. 1993;16:542547.
  • 26
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:17511756.
  • 27
    Moser M. Can the cost of care be contained and quality of care maintained in the management of hypertension? Arch Intern Med. 1994;154:16651672.
  • 28
    Moser M. Hypertension can be treated effectively without increasing the cost of care. J Human Hypertens. 1996;10(suppl 2):S33S38.
  • 29
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345:861869.
  • 30
    Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 31
    Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO HOPE substudy. Lancet. 2000;255:253259.
  • 32
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). N Engl J Med. 2001;345:851860.
  • 33
    Agodoa L, Appel L, Bakris G, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis, African American Study of Kidney Disease (AASK). A randomized controlled trial. JAMA. 2001;285:27192728.
  • 34
    Parving HH, Lennert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan Microalbuminuria Type II Diabetes in Hypertensive Patients (IRMA II). N Engl J Med. 2001;345:870878.
  • 35
    Moser M. Diuretics revisited—again. J Clin Hypertens. 2001;3:136138.
  • 36
    Moser M. Myths, Misconceptions and Heroics—The Story of the Treatment of Hypertension from the 1930s. Darien , CT : Le Jacq Communications, Inc.; 2002.